School of Mechanical Engineering and Automation, Harbin Institute of Technology, Shenzhen 518055, China; Engineering Science and Mechanics Department, The Pennsylvania State University, State College, PA 16801, USA; The Huck Institutes of the Life Sciences, The Pennsylvania State University, State College, PA 16801, USA.
Department of Surgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA 17033, USA.
Trends Biotechnol. 2020 Jun;38(6):594-605. doi: 10.1016/j.tibtech.2020.01.004. Epub 2020 Feb 24.
3D bioprinting directly into injured sites in a surgical setting, intraoperative bioprinting (IOB), is an effective process, in which the defect information can be rapidly acquired and then repaired via bioprinting on a live subject. In patients needing tissue resection, debridement, traumatic reconstruction, or fracture repair, the ability to scan and bioprint immediately following surgical preparation of the defect site has great potential to improve the precision and efficiency of these procedures. In this opinion article, we provide the reader with current major limitations of IOB from engineering and clinical points of view, as well as possibilities of future translation of bioprinting technologies from bench to bedside, and expound our perspectives in the context of IOB of composite and vascularized tissues.
3D 生物打印直接在手术现场的受损部位进行,即术中生物打印(IOB),是一种有效的方法,可快速获取缺陷信息,然后通过在活体上进行生物打印来修复。对于需要组织切除、清创、创伤重建或骨折修复的患者,在准备好缺陷部位的手术之后立即进行扫描和生物打印,这极大地提高了这些手术的精准度和效率。在这篇观点文章中,我们从工程和临床的角度为读者提供了 IOB 的当前主要局限性,以及将生物打印技术从实验室转化到临床应用的可能性,并结合复合组织和血管化组织的 IOB 阐述了我们的观点。